Entera Bio Company Insiders
| ENTX Stock | USD 2.52 0.46 15.44% |
Entera Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Entera Bio suggests that vertually all insiders are extremely bullish. Entera Bio employs about 17 people. The company is managed by 21 executives with a total tenure of roughly 134 years, averaging almost 6.0 years of service per executive, having 0.81 employees per reported executive.
| Adam Gridley CEO CEO |
| Phillip Schwartz CEO CEO, Director |
Entera Bio's Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-01-12 | Haya Taitel | Acquired 9500 @ 0.99 | View | ||
| 2024-01-10 | Haya Taitel | Acquired 7615 @ 0.77 | View | ||
| 2023-12-22 | Miranda Jayne Toledano | Acquired 23952 @ 0.71 | View | ||
| 2023-08-21 | Sean Ellis | Acquired 40000 @ 0.6 | View |
Monitoring Entera Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Entera |
Entera Bio's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Entera Bio's future performance. Based on our forecasts, it is anticipated that Entera will maintain a workforce of slightly above 20 employees by May 2024.Entera Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.4465) % which means that it has lost $0.4465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.803) %, meaning that it created substantial loss on money invested by shareholders. Entera Bio's management efficiency ratios could be used to measure how well Entera Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.79 in 2024. Return On Capital Employed is likely to drop to -0.88 in 2024. At this time, Entera Bio's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.2 M in 2024, whereas Other Current Assets are likely to drop slightly above 188.5 K in 2024.Common Stock Shares Outstanding is likely to drop to about 19.3 M in 2024. Net Loss is likely to drop to about (12.4 M) in 2024
Entera Bio Workforce Comparison
Entera Bio is rated # 3 in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 87.0. Entera Bio retains roughly 17.0 in number of employees claiming about 20% of equities under Health Care industry.
Entera Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Entera Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Taitel Haya over three months ago Purchase by Taitel Haya of 9500 shares of Entera Bio | ||
Taitel Haya over three months ago Purchase by Taitel Haya of 7615 shares of Entera Bio | ||
Gerald Lieberman over three months ago Purchase by Gerald Lieberman of 23952 shares of Entera Bio | ||
Taitel Haya over six months ago Acquisition by Taitel Haya of 33368 shares of Entera Bio subject to Rule 16b-3 | ||
Taitel Haya over six months ago Purchase by Taitel Haya of 18000 shares of Entera Bio | ||
Gerald Lieberman over six months ago Purchase by Gerald Lieberman of 20000 shares of Entera Bio | ||
Sean Ellis over six months ago Purchase by Sean Ellis of 40000 shares of Entera Bio | ||
Hillel Galitzer over six months ago Acquisition by Hillel Galitzer of 210000 shares of Entera Bio subject to Rule 16b-3 |
Entera Bio Notable Stakeholders
An Entera Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Entera Bio often face trade-offs trying to please all of them. Entera Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Entera Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Adam Gridley | CEO | Profile | |
| Phillip Schwartz | CEO, Director | Profile | |
| Gerald Lieberman | Chairman of the Board | Profile | |
| Dana YaacovGarbeli | Interim CFO | Profile | |
| Mira Rosenzweig | CFO | Profile | |
| Hillel Galitzer | COO | Profile | |
| Miranda Toledano | Independent Director | Profile | |
| Sean Ellis | Director | Profile | |
| Gerald Ostrov | Independent Director | Profile | |
| Chaim Davis | Director | Profile | |
| David Ami | Director | Profile | |
| Zeev Bronfeld | Director | Profile | |
| Yeonatan Malca | Director | Profile | |
| Roger Garceau | Director | Profile | |
| Faith Charles | Independent Director | Profile | |
| Hillel MBA | Chief Officer | Profile | |
| Miranda MBA | CEO Director | Profile | |
| Dana CPA | Chief Officer | Profile | |
| II MD | Chief Officer | Profile | |
| Arthur Santora | Chief Medical Officer | Profile | |
| Miriam Blum | Chief Medical Officer | Profile |
About Entera Bio Management Performance
The success or failure of an entity such as Entera Bio often depends on how effective the management is. Entera Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Entera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Entera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.79) | |
| Return On Capital Employed | (0.84) | (0.88) | |
| Return On Assets | (0.76) | (0.79) | |
| Return On Equity | (0.86) | (0.90) |
The data published in Entera Bio's official financial statements usually reflect Entera Bio's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Entera Bio. For example, before you start analyzing numbers published by Entera accountants, it's critical to develop an understanding of what Entera Bio's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Entera Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Entera Bio's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Entera Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Entera Bio. Please utilize our Beneish M Score to check the likelihood of Entera Bio's management manipulating its earnings.
Entera Bio Workforce Analysis
Traditionally, organizations such as Entera Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Entera Bio within its industry.Entera Bio Manpower Efficiency
Return on Entera Bio Manpower
| Revenue Per Employee | 824 | |
| Revenue Per Executive | 667 | |
| Net Loss Per Employee | 522.9K | |
| Net Loss Per Executive | 423.3K | |
| Working Capital Per Employee | 598K | |
| Working Capital Per Executive | 484.1K |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Entera Stock analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.31) | Quarterly Revenue Growth (0.92) | Return On Assets (0.45) | Return On Equity (0.80) |
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Entera Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.